ArticleDermatologic Toxicity in a Patient Receiving Liposomal DoxorubicinAuthor:Kristen N. Richards, MDPublish date: February 9, 2015 Liposomal doxorubicin hydrochloride is an anthracycline topoisomerase inhibitor indicated for ovarian cancer, AIDS-related Kaposi sarcoma, and mul...Read More